Korea Botox Rivalry To Intensify After Meditoxin Measures
Punitive Steps To Impact Market
Executive Summary
As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.
You may also be interested in...
Medytox Faces Botulinum Approval Cancellation Over Data Issues
Leading South Korean botulinum toxin company Medytox is facing substantial business risk as its Meditoxin product is suspended amid test result manipulation investigations.
SK Bioscience Readies $1.3bn IPO Amid Rosy Vaccine Outlook
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
OliX Diversifies Into mRNA Amid Growing Global Interest
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.
Need a specific report? 1000+ reports available
Buy Reports